These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 25113655)

  • 41. Feasibility of home infusion and self-administration of nanofiltered C1 esterase inhibitor for routine prophylaxis in patients with hereditary angioedema and characterization of a training and support program.
    Gregory C; Landmesser LM; Corrigan L; Mariano D
    J Infus Nurs; 2014; 37(1):29-34. PubMed ID: 24384882
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term prophylaxis therapy in patients with hereditary angioedema with C1 inhibitor deficiency.
    Craig T; Busse P; Gower RG; Johnston DT; Kashkin JM; Li HH; Lumry WR; Riedl MA; Soteres D
    Ann Allergy Asthma Immunol; 2018 Dec; 121(6):673-679. PubMed ID: 30056152
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hereditary angioedema: a survey of UK emergency departments and recommendations for management.
    Jaiganesh T; Hughan C; Webster A; Bethune C
    Eur J Emerg Med; 2012 Aug; 19(4):271-4. PubMed ID: 22008588
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Is there a need for clinical guidelines in the United States for the diagnosis of hereditary angioedema and the screening of family members of affected patients?
    Lunn ML; Santos CB; Craig TJ
    Ann Allergy Asthma Immunol; 2010 Mar; 104(3):211-4. PubMed ID: 20377110
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®) in patients with hereditary angioedema: the SABHA study.
    Zanichelli A; Azin GM; Cristina F; Vacchini R; Caballero T
    Orphanet J Rare Dis; 2018 Apr; 13(1):51. PubMed ID: 29631595
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hereditary angioedema from the patient's perspective: A follow-up patient survey.
    Banerji A; Li Y; Busse P; Riedl MA; Holtzman NS; Li HH; Davis-Lorton M; Bernstein JA; Frank M; Castaldo AJ; Long J; Zuraw B; Lumry W; Christiansen S
    Allergy Asthma Proc; 2018 May; 39(3):212-223. PubMed ID: 29669666
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hereditary angioedema: a clinical review for the otolaryngologist.
    Anon JB
    Ear Nose Throat J; 2011 Jan; 90(1):32-9. PubMed ID: 21229509
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Specialist Advice Support for Management of Severe Hereditary Angioedema Attacks: A Multicenter Cluster-Randomized Controlled Trial.
    Javaud N; Fain O; Durand-Zaleski I; Launay D; Bouillet L; Gompel A; Sobel A; Woimant M; Rabetrano H; Petrovic T; Lapostolle F; Boccon-Gibod I; Reuter PG; Bertrand P; Mezaour M; Coppere B; Floccard B; Kanny G; Baker E; Martin L; Vicaut E; Adnet F
    Ann Emerg Med; 2018 Aug; 72(2):194-203.e1. PubMed ID: 29503044
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.
    Lumry WR; Craig T; Zuraw B; Longhurst H; Baker J; Li HH; Bernstein JA; Anderson J; Riedl MA; Manning ME; Keith PK; Levy DS; Caballero T; Banerji A; Gower RG; Farkas H; Lawo JP; Pragst I; Machnig T; Watson DJ
    J Allergy Clin Immunol Pract; 2018; 6(5):1733-1741.e3. PubMed ID: 29391286
    [TBL] [Abstract][Full Text] [Related]  

  • 50. C1-inhibitor therapy for hereditary angioedema attacks: prospective patient assessments of health-related quality of life.
    Bewtra AK; Levy RJ; Jacobson KW; Wasserman RL; Machnig T; Craig TJ
    Allergy Asthma Proc; 2012; 33(5):427-31. PubMed ID: 23026185
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States.
    Banerji A; Davis KH; Brown TM; Hollis K; Hunter SM; Long J; Jain G; Devercelli G
    Ann Allergy Asthma Immunol; 2020 Jun; 124(6):600-607. PubMed ID: 32169514
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: an open-label trial.
    Riedl MA; Hurewitz DS; Levy R; Busse PJ; Fitts D; Kalfus I
    Ann Allergy Asthma Immunol; 2012 Jan; 108(1):49-53. PubMed ID: 22192966
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recombinant human C1 esterase inhibitor in the management of hereditary angioedema.
    Riedl M
    Clin Drug Investig; 2015 Jul; 35(7):407-17. PubMed ID: 26091744
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey.
    Longhurst HJ; Zanichelli A; Caballero T; Bouillet L; Aberer W; Maurer M; Fain O; Fabien V; Andresen I;
    Clin Exp Immunol; 2017 Apr; 188(1):148-153. PubMed ID: 27936514
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Self-administration of icatibant in acute attacks of Type I hereditary angioedema: A case report and review of hereditary angioedema.
    Piras V; Alves F; Gonçalo M
    Dermatol Ther; 2019 Nov; 32(6):e13098. PubMed ID: 31579975
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Disease Burden and Societal Costs of Hereditary Angioedema.
    Fijen LM; Klein PCG; Cohn DM; Kanters TA
    J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2468-2475.e2. PubMed ID: 36990433
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of Children With Hereditary Angioedema Due to C1 Inhibitor Deficiency.
    Frank MM; Zuraw B; Banerji A; Bernstein JA; Craig T; Busse P; Christiansen S; Davis-Lorton M; Li HH; Lumry WR; Riedl M;
    Pediatrics; 2016 Nov; 138(5):. PubMed ID: 27940765
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Short-term prophylaxis in patients with angioedema due to C1-inhibitor deficiency undergoing dental procedures: An observational study.
    Zanichelli A; Ghezzi M; Santicchia I; Vacchini R; Cicardi M; Sparaco A; Donati G; Ranìa V; Busa A
    PLoS One; 2020; 15(3):e0230128. PubMed ID: 32163480
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development of a disease-specific quality of life questionnaire for adult patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-QoL): Spanish multi-centre research project.
    Prior N; Remor E; Gómez-Traseira C; López-Serrano C; Cabañas R; Contreras J; Campos Á; Cardona V; Cimbollek S; González-Quevedo T; Guilarte M; de Rojas DH; Marcos C; Rubio M; Tejedor-Alonso MÁ; Caballero T
    Health Qual Life Outcomes; 2012 Jul; 10():82. PubMed ID: 22817696
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of hereditary angioedema due to C1 inhibitor deficiency in Argentina.
    Malbrán E; Menéndez A; Malbrán A
    Medicina (B Aires); 2017; 77(4):279-282. PubMed ID: 28825570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.